Ost-müük Monopar Therapeutics Inc. - MNPR CFD
Lisa lemmikuks- Kokkuvõte
- Ajaloolised andmed
- Sündmused
- Tuluaruanne
- Bilanss
- Rahavood
- Omand
Kauplemistingimused
| Hinnavahe | - | ||||||||
|
Pika positsiooni ööpäeva tasu
Long position overnight fee
Mine platvormile | -0.024068% | ||||||||
|
Lühikese positsiooni ööpäeva tasu
Short position overnight fee
Mine platvormile | 0.001846% | ||||||||
| Ööpäeva tasu aeg | 21:00 (UTC) | ||||||||
| Min kauplemise kogus | 1 | ||||||||
| Valuuta | USD | ||||||||
| Tagatis | 20% | ||||||||
| Aktsiabörs | United States of America | ||||||||
| Kauplemise vahendustasu | 0% |
*Information provided by Capital.com
Võtmestatistika
| Eelmine sulgemine* | N/A |
| Avatud* | N/A |
| Aastane muutus* | N/A |
| Päeva ulatus* | N/A |
| 52 nädala ulatus | 1.39-4.88 |
| Keskmine maht (10 päeva) | 9,030.00 |
| Keskmine maht (3 kuud) | 462.43K |
| Turukapitalisatsioon | 37.47M |
| P/E suhtarv | -100.00K |
| Ringluses olevad aktsiad | 13.19M |
| Tulu | N/A |
| EPS | -0.83 |
| Dividendid (% kasumist) | N/A |
| Beeta | -100.00K |
| Järgmine tuluaruande kuupäev | May 10, 2023 |
Kõigi andmete allikas on Refinitiv, välja arvatud tärniga märgitud, kus *-ga andmed on esitanud Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Sulgemishind | Change (%) | Avamishind | High | Low |
|---|
Monopar Therapeutics Inc. Events
| Kellaaeg (UTC) (UTC) | Riik | Sündmus |
|---|---|---|
| No events scheduled | ||
- Aastas
- Kvartalis
| 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|
| Kogutulu | 0 | 0 | 0 | 0 | 0 |
| Tulu | 0 | 0 | 0 | ||
| Kogu tegevuskulu | 9.12725 | 6.50888 | 4.32376 | 3.33115 | 16.6031 |
| Müük/Üldine/admin kulud, kokku | 2.63404 | 2.44368 | 2.35524 | 1.55669 | 1.16619 |
| Uuringud ja arendus | 6.49321 | 4.0652 | 1.96852 | 1.77445 | 15.4369 |
| Tulud majandustegevusest | -9.12725 | -6.50888 | -4.32376 | -3.33115 | -16.6031 |
| Intressitulud (kulu), muud tulud, neto | 0.02402 | 0.0819 | 0.09889 | 0.10322 | 0.04826 |
| Netotulu enne makse | -9.10322 | -6.30457 | -4.22487 | -3.22793 | -16.5549 |
| Netotulu pärast makse | -9.10322 | -6.30457 | -4.22487 | -3.22793 | -16.5549 |
| Netotulu enne erikulusid | -9.10322 | -6.30457 | -4.22487 | -3.22793 | -16.5549 |
| Netotulu | -9.10322 | -6.30457 | -4.22487 | -3.22793 | -16.5549 |
| Arvestatav tulu, v a erikulud | -9.10322 | -6.30457 | -4.22487 | -3.22793 | -16.5549 |
| Arvestatav tulu, koos erikuludega | -9.10322 | -6.30457 | -4.22487 | -3.22793 | -16.5549 |
| Jaotamisele kuuluv netotulu | -9.10322 | -6.30457 | -4.22487 | -3.22793 | -16.5549 |
| Keskmine jaotamisele kuuluv aktsia kohta | 12.4722 | 10.9583 | 10.421 | 10.421 | 10.421 |
| Jaotatav EPS, v a erakorralised kulud | -0.72988 | -0.57533 | -0.40542 | -0.30975 | -1.58861 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | |||
| Jaotamisele kuuluv normaal-EPS | -0.72988 | -0.57533 | -0.40542 | -0.30975 | -1.58861 |
| Muud, neto | 0 | 0.1224 |
| Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
|---|---|---|---|---|---|
| Kogutulu | 0 | 0 | 0 | 0 | 0 |
| Kogu tegevuskulu | 2.45719 | 2.68112 | 2.45902 | 2.0924 | 1.89472 |
| Müük/Üldine/admin kulud, kokku | 0.77925 | 0.69844 | 0.6317 | 0.61597 | 0.68794 |
| Uuringud ja arendus | 1.67793 | 1.98268 | 1.82732 | 1.47643 | 1.20678 |
| Tulud majandustegevusest | -2.45719 | -2.68112 | -2.45902 | -2.0924 | -1.89472 |
| Intressitulud (kulu), muud tulud, neto | 0.00046 | 0.00053 | 0.00058 | 0.01223 | 0.0107 |
| Netotulu enne makse | -2.45672 | -2.68059 | -2.45844 | -2.08017 | -1.88402 |
| Netotulu pärast makse | -2.45672 | -2.68059 | -2.45844 | -2.08017 | -1.88402 |
| Netotulu enne erikulusid | -2.45672 | -2.68059 | -2.45844 | -2.08017 | -1.88402 |
| Netotulu | -2.45672 | -2.68059 | -2.45844 | -2.08017 | -1.88402 |
| Arvestatav tulu, v a erikulud | -2.45672 | -2.68059 | -2.45844 | -2.08017 | -1.88402 |
| Arvestatav tulu, koos erikuludega | -2.45672 | -2.68059 | -2.45844 | -2.08017 | -1.88402 |
| Jaotamisele kuuluv netotulu | -2.45672 | -2.68059 | -2.45844 | -2.08017 | -1.88402 |
| Keskmine jaotamisele kuuluv aktsia kohta | 12.6044 | 12.5919 | 12.5827 | 12.5699 | 12.1394 |
| Jaotatav EPS, v a erakorralised kulud | -0.19491 | -0.21288 | -0.19538 | -0.16549 | -0.1552 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Jaotamisele kuuluv normaal-EPS | -0.19491 | -0.21288 | -0.19538 | -0.16549 | -0.1552 |
- Aastas
- Kvartalis
| 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|
| Käibevarad kokku | 20.5216 | 16.7998 | 13.2296 | 7.25222 | 9.13124 |
| Raha ja lühiajalised investeeringud | 20.3039 | 16.7371 | 13.2139 | 6.89277 | 8.98189 |
| Raha ja ekvivalendid | 20.3039 | 16.7371 | 13.2139 | 6.89277 | 8.98189 |
| Other Current Assets, Total | 0.21775 | 0.06269 | 0.01571 | 0.35945 | 0.14934 |
| Total Assets | 20.5216 | 16.8687 | 13.352 | 7.31796 | 9.93127 |
| Other Long Term Assets, Total | 0 | 0.06886 | 0.12238 | 0.06573 | 0.80003 |
| Total Current Liabilities | 1.58054 | 1.17667 | 0.72417 | 0.39955 | 0.31187 |
| Payable/Accrued | 1.58054 | 1.17667 | 0.72417 | 0.39955 | 0.31187 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 1.58054 | 1.17667 | 0.72417 | 0.39955 | 0.31187 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 18.9411 | 15.692 | 12.6279 | 6.9184 | 9.6194 |
| Preferred Stock - Non Redeemable, Net | |||||
| Common Stock | 0.0126 | 0.01145 | 0.01059 | 0.00929 | 0.00929 |
| Additional Paid-In Capital | 60.22 | 47.8736 | 38.5088 | 28.5672 | 28.0379 |
| Other Equity, Total | -0.00316 | -0.00787 | -0.01097 | -0.0024 | -18.4278 |
| Total Liabilities & Shareholders’ Equity | 20.5216 | 16.8687 | 13.352 | 7.31796 | 9.93127 |
| Total Common Shares Outstanding | 12.5981 | 11.4535 | 10.6215 | 10.421 | 10.421 |
| Retained Earnings (Accumulated Deficit) | -41.2884 | -32.1852 | -25.8806 | -21.6557 |
| Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
|---|---|---|---|---|---|
| Käibevarad kokku | 18.0127 | 20.5216 | 22.4484 | 24.3884 | 25.8377 |
| Raha ja lühiajalised investeeringud | 17.819 | 20.3039 | 22.3416 | 24.2929 | 25.7231 |
| Raha ja ekvivalendid | 17.819 | 20.3039 | 22.3416 | 24.2929 | 25.7231 |
| Other Current Assets, Total | 0.19364 | 0.21775 | 0.1068 | 0.09556 | 0.11457 |
| Total Assets | 18.0664 | 20.5216 | 22.5172 | 24.4573 | 25.9065 |
| Other Long Term Assets, Total | 0 | 0.06886 | 0.06886 | 0.06886 | |
| Total Current Liabilities | 1.07412 | 1.58054 | 1.23994 | 1.10364 | 0.80627 |
| Payable/Accrued | 1.04815 | 1.58054 | 1.23994 | 1.10364 | 0.80627 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 1.09946 | 1.58054 | 1.23994 | 1.10364 | 0.80627 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 16.9669 | 18.9411 | 21.2773 | 23.3536 | 25.1003 |
| Common Stock | 0.01262 | 0.0126 | 0.01259 | 0.01258 | 0.01257 |
| Additional Paid-In Capital | 60.7031 | 60.22 | 59.8776 | 59.4955 | 59.162 |
| Retained Earnings (Accumulated Deficit) | -43.7451 | -41.2884 | -38.6078 | -36.1493 | -34.0692 |
| Other Equity, Total | -0.00374 | -0.00316 | -0.00515 | -0.00516 | -0.0051 |
| Total Liabilities & Shareholders’ Equity | 18.0664 | 20.5216 | 22.5172 | 24.4573 | 25.9065 |
| Total Common Shares Outstanding | 12.6206 | 12.5981 | 12.5906 | 12.5827 | 12.5699 |
| Property/Plant/Equipment, Total - Net | 0.05369 | ||||
| Accrued Expenses | 0.02598 | ||||
| Other Liabilities, Total | 0.02534 |
- Aastas
- Kvartalis
| 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|
| Netotulu/algväärtus | -9.10322 | -6.30457 | -4.22487 | -3.22793 | -16.5549 |
| Raha majandustegevusest | -7.3174 | -4.66227 | -3.01768 | -2.68049 | -2.62747 |
| Mittelikviidsed varad | 1.46805 | 1.19849 | 1.01117 | 0.52933 | 13.8068 |
| Muutused tööjõus | 0.31777 | 0.44381 | 0.19602 | 0.01811 | 0.12058 |
| Rahavood investeeringutelt | 10.8795 | 8.18212 | 9.34741 | -0.20627 | 9.53639 |
| Rahavoogudesse investeerimine | -0.06325 | -0.11557 | -0.98481 | -0.20627 | 4.83074 |
| Aktsiate emiteerimine (tagasiost), neto | 10.9428 | 8.17529 | 10.3322 | 0 | 4.70565 |
| Rahaline kogumuutus | 3.56676 | 3.52318 | 6.32116 | -2.88915 | 6.90892 |
| Muutused valuutakursside kõikumisest | 0.00462 | 0.00333 | -0.00857 | -0.0024 | |
| Cash Taxes Paid | 0 | -0.0111 | |||
| Laenu väljastamine (kustutamine), neto | 0.1224 |
| Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -2.45672 | -9.10322 | -6.42263 | -3.96419 | -1.88402 |
| Cash From Operating Activities | -2.4675 | -7.3174 | -5.2855 | -3.34418 | -1.93806 |
| Non-Cash Items | 0.49981 | 1.46805 | 1.11789 | 0.72583 | 0.36823 |
| Changes in Working Capital | -0.51059 | 0.31777 | 0.01925 | -0.10582 | -0.42227 |
| Cash From Financing Activities | -0.01667 | 10.8795 | 10.8873 | 10.8973 | 10.9213 |
| Financing Cash Flow Items | -0.01667 | -0.06325 | -0.05548 | -0.0455 | -0.0215 |
| Issuance (Retirement) of Stock, Net | 0 | 10.9428 | 10.9428 | 10.9428 | 10.9428 |
| Foreign Exchange Effects | -0.00066 | 0.00462 | 0.00264 | 0.00263 | 0.00277 |
| Net Change in Cash | -2.48483 | 3.56676 | 5.60446 | 7.55574 | 8.986 |
| Issuance (Retirement) of Debt, Net | 0 | 0 |
| Investori nimi | Investori liik | Ringluse protsent | Hoitud osakud | Muutus osakutes | Hoidmise kuupäev | Hinnang käibele |
|---|---|---|---|---|---|---|
| Tacticgem LLC | Corporation | 31.8202 | 4111273 | 0 | 2022-04-15 | LOW |
| Gem Pharmaceuticals LLC | Corporation | 23.648 | 3055394 | 0 | 2022-04-15 | LOW |
| Hendricks (Diane) | Individual Investor | 3.628 | 468750 | 0 | 2022-04-15 | LOW |
| Brown Michael J | Individual Investor | 1.7471 | 225730 | 2859 | 2022-12-31 | LOW |
| Tactic Pharma LLC | Corporation | 1.29 | 166667 | 0 | 2022-04-15 | LOW |
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 0.7738 | 99976 | 97 | 2022-12-31 | LOW |
| Robinson (Chandler D) | Individual Investor | 0.5939 | 76730 | 4396 | 2023-01-01 | LOW |
| Starr (Christopher M) | Individual Investor | 0.5041 | 65130 | 2859 | 2022-12-31 | LOW |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.3242 | 41892 | 2721 | 2022-12-31 | LOW |
| Cittadine (Andrew) | Individual Investor | 0.2082 | 26894 | 2656 | 2022-12-31 | HIGH |
| Northern Trust Investments, Inc. | Investment Advisor/Hedge Fund | 0.1771 | 22884 | -293 | 2022-12-31 | LOW |
| Mazar (Andrew Paul) | Individual Investor | 0.1712 | 22125 | 0 | 2022-04-15 | LOW |
| Klausner (Arthur J) | Individual Investor | 0.1604 | 20730 | 2859 | 2022-12-31 | LOW |
| Tsuchimoto (Kim R) | Individual Investor | 0.1432 | 18507 | 728 | 2023-01-01 | MED |
| Anderson (Raymond William) | Individual Investor | 0.1295 | 16730 | 2859 | 2022-12-31 | MED |
| Northern Trust Global Investments | Investment Advisor | 0.1021 | 13197 | 0 | 2022-12-31 | LOW |
| Morgan Stanley Smith Barney LLC | Investment Advisor | 0.031 | 4000 | 0 | 2022-12-31 | LOW |
| UBS Financial Services, Inc. | Investment Advisor | 0.0244 | 3154 | -2245 | 2022-12-31 | LOW |
| Tower Research Capital LLC | Hedge Fund | 0.0219 | 2831 | -300 | 2022-12-31 | HIGH |
| Paragon Wealth Strategies, LLC | Investment Advisor | 0.0004 | 58 | 0 | 2022-12-31 | HIGH |
Miks valida Capital.com? Meie numbrid räägivad iseenda eest.
Capital.com Group500K+
Kauplejad
92K+
Igakuiste aktiivsete klientide arv
$53M+
Igakuine investeerimise maht
$30M+
Igakuiselt välja võetud
Kauplemiskalkulaator
Arvutage oma hüpoteetiline võit/kaotus, kui oleksite avanud CFD-tehingu ühel kindlal kuupäeval (valige kuupäev) ja sulgenud teisel kuupäeval (valige kuupäev).
Kauplemise vahendustasu
0
- 1:1
Finantsvõimendus
1:1
- 20
- 100
- 500
- 1000
- 10000
Investeering
Tehingu suurus (võimendus x investeering):
Avamishind
Close
Lühike Pikk
Monopar Therapeutics Inc. Company profile
Ettevõttest Monopar Therapeutics Inc.
Monopar Therapeutics Inc. on kliinilise faasi biofarmatseutiline ettevõte. Ettevõte keskendub peamiselt vähipatsientidele mõeldud ravimite väljatöötamisele. Selle tooteprogrammi kuuluvad Validive, kamsirubitsiin, MNPR-101 ja MNPR-202. Validive on esmaklassiline mukoadhesiivne bukaalne tablett kiiritusest põhjustatud raske suuõõne mukosiidi (SOM) ennetamiseks orofarüngeaalsetel vähipatsientidel. Selle kamsirubitsiin on kliinilises staadiumis olev topoisomeraas II-alfa selektiivne doksorubitsiini uudne analoog, mis on spetsiaalselt loodud selleks, et säilitada vähivastane toime, minimeerides samal ajal toksilist mõju südamele. MNPR-101 on humaniseeritud monoklonaalne antikeha, mis on loodud siduma vähirakkudel leiduvat spetsiifilist rakupinna retseptorit, urokinaasiplasminogeeni aktivaatori retseptorit (uPAR), ning katkestama mitmeid kasvajate kasvuks ja progresseerumiseks vajalikke radu. MNPR-202 on varajases staadiumis kamsirubitsiini analoog erinevate vähivormide puhul.
| Industry: | Biotechnology & Medical Research (NEC) |
1000 Skokie Blvd Ste 350
WILMETTE
ILLINOIS 60091-1146
US
Tuluaruanne
- Annual
- Quarterly
Teised on vaadanud veel
Kas otsite jätkuvalt vahendajat, keda saab usaldada?
Ühinege 500,000+ kauplejaga üle kogu maailma, kes valisid kauplemiseks veebisaidi Capital.com